These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 31049148)
1. HDL and Reverse Cholesterol Transport Biomarkers. Riggs KA; Rohatgi A Methodist Debakey Cardiovasc J; 2019; 15(1):39-46. PubMed ID: 31049148 [TBL] [Abstract][Full Text] [Related]
2. Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability. Rosales C; Gillard BK; Xu B; Gotto AM; Pownall HJ Methodist Debakey Cardiovasc J; 2019; 15(1):47-54. PubMed ID: 31049149 [TBL] [Abstract][Full Text] [Related]
3. Dyslipidaemia: Revealing the effect of CETP inhibition in cardiovascular disease. Holmes MV; Smith GD Nat Rev Cardiol; 2017 Nov; 14(11):635-636. PubMed ID: 28980665 [TBL] [Abstract][Full Text] [Related]
4. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both. Nicholls SJ Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215 [TBL] [Abstract][Full Text] [Related]
6. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350 [TBL] [Abstract][Full Text] [Related]
7. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside. Karalis I; Rensen PC; Jukema JW Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310 [No Abstract] [Full Text] [Related]
10. Therapeutic targets to raise HDL in patients at risk or with coronary artery disease. Lüscher TF; von Eckardstein A; Simic B Curr Vasc Pharmacol; 2012 Nov; 10(6):720-4. PubMed ID: 23259565 [TBL] [Abstract][Full Text] [Related]
11. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430 [TBL] [Abstract][Full Text] [Related]
12. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406 [TBL] [Abstract][Full Text] [Related]
13. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis. Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690 [TBL] [Abstract][Full Text] [Related]
14. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. Tardif JC; Rhainds D; Brodeur M; Feroz Zada Y; Fouodjio R; Provost S; Boulé M; Alem S; Grégoire JC; L'Allier PL; Ibrahim R; Guertin MC; Mongrain I; Olsson AG; Schwartz GG; Rhéaume E; Dubé MP Circ Cardiovasc Genet; 2016 Aug; 9(4):340-8. PubMed ID: 27418594 [TBL] [Abstract][Full Text] [Related]
15. From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease. Sacks FM; Jensen MK Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):487-499. PubMed ID: 29371248 [TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987 [TBL] [Abstract][Full Text] [Related]
20. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]